Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing

Oruka reported positive Week 28 Phase 2a data for psoriasis candidate ORKA-001, with PASI 100 improving to 71.4% (45/63) and PASI 90 reaching 87.3% (55/63), six months after patients' last dose. The drug maintained an IL-23-class-consistent safety profile, with upper respiratory infection the only adverse event occurring in at least 5% of patients and no injection-site reactions. Key catalysts are full 52-week EVERLAST-A data in December 2026 and Phase 2b EVERLAST-B data in 4Q 2026.

Analysis

The investable question is not whether ORKA-001 is active, but whether durability can support a commercially differentiated maintenance interval versus established IL-23 therapies. A twice-yearly regimen could reduce administration friction and improve persistence, but it may also weaken annual drug revenue per patient unless Oruka achieves a premium price or materially expands treated-patient share. The relevant competitive pressure falls on AbbVie (ABBV; Skyrizi), Johnson & Johnson (JNJ; Tremfya), and UCB (UCB.BR; Bimzelx), though incumbents retain major advantages in long-term safety databases, payer contracting, and broad-label infrastructure.

Near-term, the update should improve ORKA's probability-of-success and support a positive trading response, but the small Phase 2 dataset cannot establish the two variables that matter to valuation: response durability through a full dosing interval and reproducibility in the larger Phase 2b population. The December 2026 readouts are binary catalysts; a meaningful decay in complete-clearance rates, a need for more frequent maintenance dosing, or any unexpected infection/malignancy imbalance would impair the infrequent-dosing premium and likely drive sharp multiple compression. Conversely, durable clearance with a credible annual or semiannual maintenance regimen would reposition ORKA from a single-asset cytokine follower toward a potential best-in-class adherence story.

Consensus may over-credit high complete-clearance rates while underweighting payer economics. Psoriasis formularies are designed around rebates and step edits, so clinical convenience alone may not displace deeply contracted biologics; ORKA must show that fewer injections translate into objectively better persistence, lower total medical cost, or premium efficacy across difficult patient subsets. The more non-obvious upside is in patients who discontinue current biologics because of treatment burden, while the key downside is that a longer half-life also leaves less ability to rapidly stop exposure if uncommon safety signals emerge.

No broad competitor short is warranted today: incumbent psoriasis franchises are diversified and this dataset is too early to alter their earnings trajectories. ORKA is a catalyst-driven development-stage exposure rather than a fundamentals trade until the upcoming datasets clarify maintenance dosing and the company's cash runway into registrational studies.

Key Decisions for Investors

• Maintain or initiate only a small tactical long in ORKA ahead of 4Q 2026 EVERLAST-B data; size as a binary clinical catalyst, not a core position. Add only if pullbacks are liquidity-driven rather than accompanied by evidence of durability or safety deterioration.
• For defined-risk upside, evaluate ORKA call spreads expiring after the December 2026 Week-52 release, subject to option liquidity and implied-volatility screening. Avoid naked calls if post-release implied volatility already prices a move exceeding plausible clinical upside.
• Set a pre-readout diligence gate: require disclosure supporting sustained response through Week 52, a maintenance schedule consistent with at least semiannual dosing, and no meaningful safety/ADA divergence. Failure on any of these should trigger exit or a short-bias reassessment.
• Do not short ABBV, JNJ, or UCB.BR against ORKA. Revisit a long ORKA/short psoriasis-franchise basket only after Phase 2b establishes reproducible differentiation and payer-feedback data indicate a viable premium-access pathway.
• Monitor ORKA cash balance, quarterly operating burn, and expected registrational-trial financing needs over the next 1-3 months; a financing announcement before decisive Phase 2b data could cap upside even if the clinical narrative remains intact.